Health-related quality of life correlates with time in therapeutic range in children on anticoagulants with International Normalised Ratio self-monitoring.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 25 09 2019
revised: 24 03 2020
accepted: 14 05 2020
pubmed: 19 10 2020
medline: 20 1 2021
entrez: 18 10 2020
Statut: ppublish

Résumé

Managing oral anticoagulant therapy with vitamin K antagonists remains challenging in paediatric medicine. This study aimed to assess the correlation between time in therapeutic range and quality of life in children participating in a non-selective International Normalised Ratio self-monitoring and vitamin K antagonist education programme. Children aged from 2 to 18 years and receiving vitamin K antagonist therapy were eligible for this prospective multicentre study. Clinical and demographic data were collected. Health-related quality of life was assessed using the PedsQL™ 4.0 questionnaire. Correlations between quality of life scores and time in therapeutic range were measured. A total of 121 children were included in the study (mean age 9.6±4.9 years). Cardiac conditions were the predominant indication for vitamin K antagonists. The mean time in therapeutic range was 0.78±0.15 overall, and 0.76±0.24 over the 3-month period before quality of life assessment. The mean total quality of life score was 76.2±18 in self reports, 71.4±22 in mother reports and 73.5±19 in father reports. The time in therapeutic range correlated with the total quality of life scores in self reports (r=0.22; P=0.04), mother reports (r=0.23; P=0.02) and father reports (r=0.28; P=0.02). The time in therapeutic range predominantly correlated with school functioning in self reports (r=0.38; P=0.002) and mother reports (r=0.40; P<0.001), and with physical functioning in father reports (r=0.28; P=0.03). Time in therapeutic range correlated with quality of life in children participating in a non-selective International Normalised Ratio self-monitoring and vitamin K antagonist education programme. Regular assessment of quality of life in patient education programmes contributes towards understanding the concerns and needs of patients.

Sections du résumé

BACKGROUND BACKGROUND
Managing oral anticoagulant therapy with vitamin K antagonists remains challenging in paediatric medicine.
AIMS OBJECTIVE
This study aimed to assess the correlation between time in therapeutic range and quality of life in children participating in a non-selective International Normalised Ratio self-monitoring and vitamin K antagonist education programme.
METHODS METHODS
Children aged from 2 to 18 years and receiving vitamin K antagonist therapy were eligible for this prospective multicentre study. Clinical and demographic data were collected. Health-related quality of life was assessed using the PedsQL™ 4.0 questionnaire. Correlations between quality of life scores and time in therapeutic range were measured.
RESULTS RESULTS
A total of 121 children were included in the study (mean age 9.6±4.9 years). Cardiac conditions were the predominant indication for vitamin K antagonists. The mean time in therapeutic range was 0.78±0.15 overall, and 0.76±0.24 over the 3-month period before quality of life assessment. The mean total quality of life score was 76.2±18 in self reports, 71.4±22 in mother reports and 73.5±19 in father reports. The time in therapeutic range correlated with the total quality of life scores in self reports (r=0.22; P=0.04), mother reports (r=0.23; P=0.02) and father reports (r=0.28; P=0.02). The time in therapeutic range predominantly correlated with school functioning in self reports (r=0.38; P=0.002) and mother reports (r=0.40; P<0.001), and with physical functioning in father reports (r=0.28; P=0.03).
CONCLUSIONS CONCLUSIONS
Time in therapeutic range correlated with quality of life in children participating in a non-selective International Normalised Ratio self-monitoring and vitamin K antagonist education programme. Regular assessment of quality of life in patient education programmes contributes towards understanding the concerns and needs of patients.

Identifiants

pubmed: 33069639
pii: S1875-2136(20)30199-6
doi: 10.1016/j.acvd.2020.05.022
pii:
doi:

Substances chimiques

Anticoagulants 0
Vitamin K 12001-79-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

811-820

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Hamouda Abassi (H)

Paediatric and Congenital Cardiology Department, Clinical Investigation Centre, Arnaud-De-Villeneuve University Hospital, M3C Regional Reference Centre, 34295 Montpellier, France; Public Health and Chronic Diseases Laboratory, Centre for Studies and Research into Health Services and Quality of Life, Aix-Marseille University, 13385 Marseille, France.

Fanny Bajolle (F)

Paediatric Cardiology Department, Hôpital Necker-Enfants malades, AP-HP, M3C National Reference Centre, Paris-Descartes University, Sorbonne Paris Cité, 75015 Paris, France.

Oscar Werner (O)

Paediatric and Congenital Cardiology Department, Clinical Investigation Centre, Arnaud-De-Villeneuve University Hospital, M3C Regional Reference Centre, 34295 Montpellier, France; Paediatric Cardiology and Rehabilitation Unit, St-Pierre Institute, 34250 Palavas-Les-Flots, France.

Annie Auer (A)

Paediatric Cardiology and Rehabilitation Unit, St-Pierre Institute, 34250 Palavas-Les-Flots, France.

Amandine Marquina (A)

Paediatric Cardiology and Rehabilitation Unit, St-Pierre Institute, 34250 Palavas-Les-Flots, France.

Thibault Mura (T)

Epidemiology Department, University Hospital, Clinical Investigation Centre, INSERM-CIC 1411, University of Montpellier, 34295 Montpellier, France.

Kathleen Lavastre (K)

Paediatric and Congenital Cardiology Department, Clinical Investigation Centre, Arnaud-De-Villeneuve University Hospital, M3C Regional Reference Centre, 34295 Montpellier, France.

Sophie Guillaumont (S)

Paediatric Cardiology and Rehabilitation Unit, St-Pierre Institute, 34250 Palavas-Les-Flots, France.

Federico Manna (F)

Epidemiology Department, University Hospital, Clinical Investigation Centre, INSERM-CIC 1411, University of Montpellier, 34295 Montpellier, France.

Pascal Auquier (P)

Public Health and Chronic Diseases Laboratory, Centre for Studies and Research into Health Services and Quality of Life, Aix-Marseille University, 13385 Marseille, France.

Damien Bonnet (D)

Paediatric Cardiology Department, Hôpital Necker-Enfants malades, AP-HP, M3C National Reference Centre, Paris-Descartes University, Sorbonne Paris Cité, 75015 Paris, France.

Pascal Amedro (P)

Paediatric and Congenital Cardiology Department, Clinical Investigation Centre, Arnaud-De-Villeneuve University Hospital, M3C Regional Reference Centre, 34295 Montpellier, France; Public Health and Chronic Diseases Laboratory, Centre for Studies and Research into Health Services and Quality of Life, Aix-Marseille University, 13385 Marseille, France; PhyMedExp, CNRS, INSERM, University of Montpellier, 34295 Montpellier, France. Electronic address: p-amedro@chu-montpellier.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH